Abstract
Purpose
Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy; NETest monitors disease. We prospectively evaluated: (1) NETest as a surrogate biomarker for RECIST; (2) the correlation of NETest levels with PPQ prediction.
Methods
Three independent 177Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n = 72; Bad-Berka, Germany: n = 44; Rotterdam, Netherlands: n = 41). Treatment response: RECIST1.1 (responder (stable, partial, and complete response) vs non-responder). Blood sampling: pre-PRRT, before each cycle and follow-up (2–12 months). PPQ (positive/negative) and NETest (0–100 score) by PCR. Stable < 40; progressive > 40). CgA (ELISA) as comparator. Samples de-identified, measurement and analyses blinded. Kaplan–Meier survival and standard statistics.
Results
One hundred twenty-two of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p < 0.0001) decreased in RECIST “responders” (− 47 ± 3%); in “non-responders,” it remained increased (+ 79 ± 19%) (p < 0.0005). NETest monitoring accuracy was 98% (119/122). Follow-up levels > 40 (progressive) vs stable (< 40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI, 0.02–0.07).
PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p < 0.0001) decreased in PPQ-predicted responders (− 46 ± 3%) and remained elevated or increased in PPQ-predicted non-responders (+ 75 ± 19%). Follow-up NETest categories stable vs progressive significantly correlated with PPQ prediction and mPFS (not reached vs. 10 months; HR 0.06 (95%CI, 0.03–0.12).
CgA did not reflect PRRT treatment: in RECIST responders decrease in 38% and in non-responders 56% (p = NS).
Conclusions
PPQ predicts PRRT response in 97%. NETest accurately monitors PRRT response and is an effective surrogate marker of PRRT radiological response. NETest decrease identified responders and correlated (> 97%) with the pretreatment PPQ response predictor. CgA was non-informative.
Similar content being viewed by others
References
Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):179–91. https://doi.org/10.1016/j.hoc.2015.09.009.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38(12):2125–35.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer. 2017;24(5):243–51. https://doi.org/10.1530/ERC-16-0524.
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. EJNMMI. 2018;45(7):1155–69.
Zhao X, Modur V, Carayannopoulos LN, Laterza OF. Biomarkers in pharmaceutical research. Clin Chem. 2015;61(11):1343–53. https://doi.org/10.1373/clinchem.2014.231712.
Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer. 2016;16(1):850. https://doi.org/10.1186/s12885-016-2886-9.
Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37(6):e141–7. https://doi.org/10.1097/RLU.0b013e31823926e5.
Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56.
Kidd M, Modlin IM. Therapy: the role of liquid biopsies to manage and predict PRRT for NETs. Nat Rev Gastroenterol Hepatol. 2017;14(6):331–2.
Bodei L, Herrmann K, Baum RP, Kidd M, Malczewska A, Modlin IM. Caveat emptor: let our acclaim of the apotheosis of PRRT not blind us to the error of Prometheus. J Nucl Med. 2019;60(1):7–8. https://doi.org/10.2967/jnumed.118.219386.
Modlin I, Drozdov I, Kidd M. The Identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. Plos One. 2013:e63364.
Kidd M, Drozdov I, Modlin I. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr Relat Cancer. 2015;22(4):561–75. https://doi.org/10.1530/ERC-15-0092.
Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, et al. Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases. Clin Cancer Res. 2018;24(9):2182–93. https://doi.org/10.1158/078-0432.CCR-17-3378.
van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, et al. Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Front Endocrinol (Lausanne). 2018;9:740. https://doi.org/10.3389/fendo.2018.00740 eCollection 2018.
Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk A, Filosso PL, et al. NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease neuroendocrinology. Neuroendocrinology. 2019;108(3):219–31.
Liu E, Paulson S, Gulati A, Freudman J, Kafer S, Wickremesinghe P, et al. Assessment of NETest clinical utility in a US registry-based study. Oncologist. 2019;24(6):783–90.
Cwikla JB, Bodei L, Kolasinska-Cwikla A, Sankowski A, Modlin IM, Kidd M. Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J Clin Endocrinol Metab. 2015;100(11):E1437–45.
Kidd M, Modlin I, Drozdov I, Aslanian H, Bodei L, Matar S, et al. A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. Oncotarget. 2017;9(6):7182–96.
Malczewska A, Makulik K, Witkowska M, Bocian A, Walter A, Zajęcki W, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and accurately correlates with anatomical and functional imaging. Endocr Connect. 2019. https://doi.org/10.1530/EC-19-0030.
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839–51. https://doi.org/10.1007/s00259-015-3250-z.
You YN, Rustin RB, Sullivan JD. Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg Oncol. 2015;24(2):61–6. https://doi.org/10.1016/j.suronc.2015.02.001. Epub Feb 14.
Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 2017;104(2):170–82.
Malczewska A, Bodei L, Kidd M, Modlin IM. Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J Clin Endocrinol Metab. 2019;104(3):867–72. https://doi.org/10.1210/jc.2018-01804.
Oberg K, Modlin I, DeHerder W, Pavel M, Klimstra D, Frilling A, et al. Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 2015;16:e435046.
Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes. 2016;23(1):28–37. https://doi.org/10.1097/MED.0000000000000215.
Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–71. https://doi.org/10.1200/JCO.2004.04.024.
Oksuz MO, Winter L, Pfannenberg C, Reischl G, Mussig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289–300. https://doi.org/10.1016/j.diii.2013.07.006.EpubSep12.
Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grunwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55(2):183–90. https://doi.org/10.2967/jnumed.113.125336.
Oberg K. Molecular Imaging Radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics. 2012;2(5):448–58.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
All human participant procedures were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent: Informed consent was obtained from all participants in the study.
Conflict of Interest
LB, RPB, and GP—consultancy fees from Ipsen and Advanced Accelerator Applications unrelated to the submitted work (AAA). EPK and DJK—support from AAA unrelated to the submitted work. RPB—support from Ipsen, ROTOP Pharmaka, and OctreoPharm Sciences unrelated to the work. MK—employed by Wren Laboratories. IMM and IAD—consultants for Wren Laboratories. No conflicts for AS, WAvZ, SS, or AM.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Translational research
Electronic supplementary material
ESM 1
(DOCX 1540 kb)
Rights and permissions
About this article
Cite this article
Bodei, L., Kidd, M.S., Singh, A. et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest . Eur J Nucl Med Mol Imaging 47, 895–906 (2020). https://doi.org/10.1007/s00259-019-04601-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-019-04601-3